Vir Biotechnology, Inc. (VIR)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 1,214 | 3,032 | 2,380 | 3,075 |
| Selling, general and administrative | 22,283 | 23,944 | 25,744 | 30,265 |
| Restructuring, long-lived assets impairment and related charges, net | -172 | -10 | 12,712 | 26,275 |
| Research and development | 97,509 | 118,645 | 195,178 | 105,113 |
| Cost of revenue | 11 | - | 50 | 52 |
| Total operating expenses | 119,631 | 142,579 | 233,684 | 161,705 |
| Loss from operations | -118,417 | -139,547 | -231,304 | -158,630 |
| Interest income | - | - | - | 18,846 |
| Other income (expense), net | 226 | -72 | -893 | -535 |
| Interest income | 10,785 | 12,288 | 17,527 | - |
| Change in fair value of equity investments | -3,382 | 6,382 | 1,130 | 429 |
| Total other income | 7,629 | 18,598 | 17,764 | 18,740 |
| Loss before (provision for) benefit from income taxes | -110,788 | -120,949 | -213,540 | -139,890 |
| (provision for) benefit from income taxes | 170 | 16 | 177 | -1,512 |
| Net loss | - | - | -213,717 | -138,378 |
| Net loss attributable to noncontrolling interest | - | - | - | - |
| Net loss | -110,958 | -120,965 | -213,717 | -138,378 |
| Net loss per share, basic (in usd per share) | -0.8 | -0.88 | -1.56 | -1.02 |
| Net loss per share, diluted (in usd per share) | -0.8 | -0.88 | -1.56 | -1.02 |
| Weighted-average shares outstanding, basic (in shares) | 138,447,469 | 137,468,900 | 136,653,753 | 136,233,725 |
| Weighted-average shares outstanding, diluted (in shares) | 138,447,469 | 137,468,900 | 136,653,753 | 136,233,725 |